๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Marginal Zone Lymphoma
Clinical trial register · China

Marginal Zone Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 3 Guangzhou 3 Zhengzhou 3 Tianjin 3 Beijing 3
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai3 Guangzhou3 Zhengzhou3 Tianjin3 Beijing3
All 22 locations
Target enrolment
to

Marginal Zone Lymphoma trials in China

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
NCT07609446Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Observational
30
Suzhou
2026-05-01
Recruiting
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
NCT07441993Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Recruiting
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
NCT07233720Marginal Zone Lymphoma
Henan Cancer Hospital
Observational
30
Zhengzhou
2025-11-18
Recruiting
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
NCT06566807Marginal Zone Lymphoma
Huai'an First People's Hospital
Phase 2
51
Huai'an
2024-08-25
Recruiting
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
NCT06534463Marginal Zone Lymphoma
Ruijin Hospital
Observational
500
Shanghai
2024-08-02
Recruiting
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
NCT06513234Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-07-11
Recruiting
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
NCT06504940Marginal Zone Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 2
69
Hangzhou
2024-06-28
Recruiting
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
NCT06478472Marginal Zone Lymphoma
The First Affiliated Hospital of Xiamen University
Not applicable
36
Xiamen
2024-06-23
Recruiting
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
NCT06454968Marginal Zone Lymphoma
Peking Union Medical College Hospital
Phase 2
45
Beijing
2024-06-20
Recruiting
A Cohort Study in Newly Diagnosed MZL
NCT06449885Marginal Zone Lymphoma
Fudan University
Observational
2,500
Shanghai
2024-05-30
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
NCT05846750Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
59
Tianjin
2022-11-01
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/marginal-zone-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Marginal Zone Lymphoma.

How many Marginal Zone Lymphoma trials are recruiting in China?

11 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Marginal Zone Lymphoma), 14 studies
PhaseStudiesRecruitingShare
Phase 26642.9%
Observational4328.6%
Phase 32014.3%
Not applicable117.1%
Phase 1/2117.1%

Most active sponsors

Lead sponsors with the most studies (Marginal Zone Lymphoma)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China33
BeOne Medicines21
First Affiliated Hospital of Zhejiang University11
Fudan University11
Henan Cancer Hospital11
Huai'an First People's Hospital11
Incyte Corporation10
Peking Union Medical College Hospital11
Ruijin Hospital11
The First Affiliated Hospital of Soochow University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.